Literature DB >> 28823087

Reactive follicular hyperplasia on dasatinib treatment for chronic myeloid leukemia.

Alessandra Iurlo1, Cristina Bucelli2, Daniele Cattaneo2, Nicola Orofino2, Juri Alessandro Giannotta2, Manuela Zappa2, Umberto Gianelli3, Agostino Cortelezzi2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28823087     DOI： 10.1007/s00277-017-3105-8

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  3 in total

1.  Low-Dose Ponatinib in Intolerant Chronic Myeloid Leukemia Patients: A Safe and Effective Option.

Authors:  Alessandra Iurlo; Daniele Cattaneo; Nicola Orofino; Cristina Bucelli; Matteo Molica; Massimo Breccia
Journal:  Clin Drug Investig       Date:  2018-05       Impact factor: 2.859

2.  A Phase I Trial of Dasatinib and Osimertinib in TKI Naïve Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer.

Authors:  Chul Kim; Stephen V Liu; Jennifer Crawford; Tisdrey Torres; Vincent Chen; Jillian Thompson; Ming Tan; Giuseppe Esposito; Deepa S Subramaniam; Giuseppe Giaccone
Journal:  Front Oncol       Date:  2021-09-08       Impact factor: 6.244

3.  Dasatinib associated lymphadenopathy in a chronic myeloid leukemia patient: A case report.

Authors:  Dimitrios Pilalas; Triantafyllia Koletsa; Georgios Arsos; Grigorios Panselinas; Paraskevi Exadaktylou; George Polychronopoulos; Christos Savopoulos; Georgia D Kaiafa
Journal:  Medicine (Baltimore)       Date:  2020-11-06       Impact factor: 1.817
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.